Metaphore Biotechnologies utilizes its MIMiC platform, which combines machine learning with molecular mimicry, to design therapeutics that enhance function, specificity, and selectivity for challenging drug targets. The company aims to create transformative treatments that outperform existing drugs, improving patient outcomes in areas like obesity management.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many drug targets are difficult to address with conventional therapeutic approaches due to challenges in achieving sufficient function, specificity, and selectivity. This limitation hinders the development of effective treatments for complex diseases, leaving significant unmet needs in areas such as obesity management.
Solution
Metaphore Biotechnologies leverages its MIMiC platform, which integrates machine learning and molecular mimicry, to design therapeutics with enhanced functional properties. The platform facilitates the creation of treatments that outperform existing drugs by improving target interaction and selectivity. This approach enables the development of transformative therapies for challenging targets, ultimately improving patient outcomes in areas like obesity management.
Target Audience
The primary audience includes pharmaceutical companies and researchers focused on developing novel therapeutics for complex diseases, particularly in areas with high unmet needs like obesity management.
Features
- MIMiC platform combining machine learning with molecular mimicry
- Design of therapeutics with enhanced function, specificity, and selectivity
- Focus on challenging drug targets
- Development of transformative treatments that outperform existing drugs